Abstract
Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7% in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5α-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5α-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.
Keywords: Antiandrogen therapy, 5α-reductase inhibitors, androgen receptor antagonists, androgen excess
Mini-Reviews in Medicinal Chemistry
Title: Pharmacological Options for Treatment of Hyperandrogenic Disorders
Volume: 9 Issue: 9
Author(s): P. Reismann, I. Liko, P. Igaz, A. Patocs and K. Racz
Affiliation:
Keywords: Antiandrogen therapy, 5α-reductase inhibitors, androgen receptor antagonists, androgen excess
Abstract: Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7% in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5α-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5α-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.
Export Options
About this article
Cite this article as:
Reismann P., Liko I., Igaz P., Patocs A. and Racz K., Pharmacological Options for Treatment of Hyperandrogenic Disorders, Mini-Reviews in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/138955709788922692
DOI https://dx.doi.org/10.2174/138955709788922692 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ambulatory Blood Pressure Monitoring in Type 2 Diabetes Mellitus: A Cross-sectional Study
Current Hypertension Reviews Aesthetic Cardiology: Adipose-Derived Stem Cells for Myocardial Repair
Current Stem Cell Research & Therapy Effect of Glyoxal Modification on a Critical Arginine Residue (Arg-31α) of Hemoglobin: Physiological Implications of Advanced Glycated end Product an <i>in vitro</i> Study
Protein & Peptide Letters The Role of Melanocortin Peptides and Receptors in Regulation of Energy Balance
Current Pharmaceutical Design Inflammatory and Vascular Alterations in Sepsis: The Role of Nitric Oxide- Dependent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Recent Advances on Patents in Poly(Ethylene Glycol)-Based Drug Delivery
Recent Patents on Drug Delivery & Formulation Role of Neuropeptides in the Regulation of the Insect Immune System – Current Knowledge and Perspectives
Current Protein & Peptide Science Vascular and Endothelial Regeneration
Current Stem Cell Research & Therapy Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Insulin Resistance and Postprandial Hyperglycemia the Bad Companions in Natural History of Diabetes: Effects on Health of Vascular Tree
Current Diabetes Reviews A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i
Current Vascular Pharmacology Schizophrenia-associated Risk and Protective Variants of c-Fos Encoding Gene
Recent Advances in DNA & Gene Sequences (Discontinued) Can Probiotics Supplementation Improve Glycemic and Renal Status in Diabetic Nephropathy? A Systematic Review and Meta-Analysis of Clinical Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Podocytes as a Target of Insulin
Current Diabetes Reviews From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine